Proliferative Diabetic Retinopathy: Advanced Disease Management
What Is Proliferative Diabetic Retinopathy
Diabetic retinopathy is broadly classified into two categories: nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). PDR is diagnosed when the retina develops neovascularization, meaning new, abnormal blood vessels begin to form on the retinal surface or the optic disc. This growth occurs in response to widespread oxygen deprivation in the retinal tissue caused by prolonged, poorly controlled diabetes.
PDR is more likely to develop in patients who have had diabetes for many years, particularly when blood sugar, blood pressure, and cholesterol are not well controlled. Approximately 33 percent of people with diabetes over age 40 have some form of diabetic retinopathy, and among those, roughly 7 percent have proliferative diabetic retinopathy (Centers for Disease Control and Prevention). Both Type 1 and Type 2 diabetes can lead to PDR, though patients with Type 1 diabetes tend to develop it at higher rates over time. Regular diabetic eye screenings are essential for detecting early changes before the disease reaches this advanced stage.
In a healthy eye, the retina receives oxygen and nutrients through a stable network of blood vessels. In PDR, chronic high blood sugar damages these vessels so severely that large areas of the retina lose their blood supply. The body responds by producing vascular endothelial growth factor (VEGF), a protein that triggers the growth of new vessels. Unfortunately, these replacement vessels are structurally weak and prone to leaking blood and fluid into the vitreous cavity, the gel-filled space inside the eye.
How PDR Differs from Nonproliferative Diabetic Retinopathy
Nonproliferative diabetic retinopathy is the earlier stage of the disease. It is marked by microaneurysms (tiny bulges in retinal blood vessels), dot-and-blot hemorrhages, hard exudates (lipid deposits), and cotton-wool spots (areas of localized nerve fiber damage). In NPDR, the existing blood vessels are weakened but no new abnormal vessels have formed. You can learn more about how the stages of diabetic retinopathy are classified and monitored.
The defining feature that separates PDR from NPDR is neovascularization. Once new blood vessels appear on the retina or optic disc, the disease is classified as proliferative. These vessels grow along the retinal surface and can extend into the vitreous. Because they lack the structural integrity of normal vessels, they can rupture and bleed at any time, sometimes without warning.
While NPDR can often be monitored with regular exams and managed through systemic health improvements, PDR typically requires active treatment. The risk of sudden, significant vision loss is substantially higher once neovascularization is present. Tractional retinal detachment, vitreous hemorrhage, and neovascular glaucoma are all serious complications that can develop rapidly in untreated PDR.
What Causes Abnormal Blood Vessel Growth in PDR
Chronically elevated blood sugar damages the walls of the small blood vessels that nourish the retina. Over time, these vessels become leaky, swollen, or completely blocked. When enough vessels close off, entire regions of the retina are starved of oxygen, a condition known as retinal ischemia. This widespread oxygen deprivation is the primary trigger for the cascade of events that leads to PDR.
In response to ischemia, retinal cells release increased amounts of vascular endothelial growth factor (VEGF). Under normal conditions, VEGF plays a role in healthy blood vessel growth and repair. In PDR, however, VEGF is overproduced, stimulating the rapid formation of fragile, disorganized new vessels. These abnormal vessels lack the tight junctions and supportive structures found in normal retinal vasculature, making them highly susceptible to hemorrhage.
Several factors accelerate the progression toward PDR. Poorly controlled blood sugar remains the most significant risk factor, but elevated blood pressure and abnormal cholesterol levels also contribute to vascular damage. Pregnancy, kidney disease, and anemia can further increase the likelihood of developing proliferative changes. Patients with diabetic macular edema may have overlapping vascular damage that compounds their overall risk.
Symptoms of Proliferative Diabetic Retinopathy
In many cases, patients with early PDR have no symptoms at all. The abnormal new blood vessels can grow silently on the retinal surface without causing pain or noticeable vision changes. This is why our retina specialists emphasize the importance of regular dilated eye examinations for every patient with diabetes, even when vision seems normal.
When the fragile new vessels bleed into the vitreous, patients may experience a sudden increase in floaters, which are dark spots, cobwebs, or streaks drifting across their field of view. A larger bleed can cause a dramatic, sudden loss of vision or a dark curtain effect across part or all of the visual field. Some patients describe seeing reddish or dark shadows that partially obscure their sight. You can read more about the causes and management of vitreous hemorrhage as a complication of PDR.
If scar tissue forms from repeated bleeding episodes, it can pull on the retina and cause a tractional retinal detachment. Symptoms of this complication include a shadow or curtain across the peripheral or central vision, distorted or wavy vision, and a progressive decline in visual clarity. Neovascular glaucoma, another serious complication, can cause eye pain, redness, and elevated eye pressure. Any sudden vision change in a patient with diabetes should be evaluated urgently.
How PDR Is Treated
Panretinal photocoagulation (PRP), also called scatter laser treatment, has been a cornerstone of PDR management for decades. During PRP, a laser is applied to the peripheral retina in a carefully spaced pattern, creating small burns in the oxygen-deprived tissue. By reducing the metabolic demand of these ischemic areas, PRP decreases the production of VEGF and causes existing abnormal blood vessels to regress. The procedure is typically performed in one or two sessions in the office.
Anti-VEGF medications, delivered through intravitreal injection directly into the eye, have become a vital treatment for PDR. These medications block the VEGF protein that drives abnormal vessel growth, causing neovascularization to shrink. Common anti-VEGF agents include bevacizumab, ranibizumab, and aflibercept. Injections may be used as a primary treatment or in combination with PRP, and they are particularly helpful when macular edema is present alongside proliferative changes.
When PDR leads to a vitreous hemorrhage that does not clear on its own, or when tractional retinal detachment threatens central vision, vitrectomy surgery may be recommended. During a vitrectomy, our retina specialists remove the blood-filled vitreous gel and any scar tissue pulling on the retina. The vitreous is replaced with a saline solution or a gas bubble that holds the retina in place while it heals. Vitrectomy can preserve and sometimes improve vision in eyes with advanced PDR complications.
Treatment of PDR is most effective when combined with tight control of the underlying diabetes. Lowering hemoglobin A1C, managing blood pressure, and addressing cholesterol abnormalities all help slow further vascular damage and improve the response to eye-specific treatments. Our retina specialists work closely with each patient's primary care physician or endocrinologist to coordinate a comprehensive approach.
Frequently Asked Questions
PRP is performed in the office and usually takes 15 to 30 minutes per session. Your eye will be numbed with anesthetic drops, and a special contact lens is placed on the eye to focus the laser. You may feel a mild stinging or aching sensation during treatment, and your vision will be blurry for several hours afterward. Most patients need one or two sessions to complete the full treatment pattern, and you can typically resume normal activities the following day.
The injection schedule varies based on your individual response. Most patients begin with monthly injections and are monitored closely with imaging at each visit. As the abnormal blood vessels regress and the retina stabilizes, the interval between injections may be gradually extended. Some patients eventually require injections only every few months, while others may transition to PRP to reduce the long-term injection burden. Our guide on what to expect during an intravitreal injection provides more detail on how these treatments are administered.
Without treatment, PDR can lead to increasingly severe complications. Repeated vitreous hemorrhages can cause prolonged vision loss lasting weeks or months. Scar tissue formation may result in tractional retinal detachment, pulling the retina away from its supporting tissue. Neovascular glaucoma, a painful condition caused by abnormal vessel growth blocking the eye's drainage system, can also develop. Each of these complications makes treatment more complex and reduces the likelihood of full vision recovery.
PDR is one of the leading causes of preventable blindness in working-age adults. If left untreated, the cumulative effects of vitreous hemorrhage, retinal detachment, and neovascular glaucoma can result in irreversible vision loss. However, with timely diagnosis and appropriate treatment, the risk of severe vision loss can be significantly reduced. This is why consistent follow-up and adherence to your treatment plan are essential.
The most effective way to prevent or delay progression to PDR is maintaining good control of blood sugar, blood pressure, and cholesterol. Keeping your hemoglobin A1C at or below the target recommended by your doctor reduces the risk of advancing from nonproliferative to proliferative disease. Annual or more frequent dilated eye examinations allow for early detection of changes that may need treatment. Patients who have already been diagnosed with diabetic retinopathy at any stage should follow their recommended monitoring schedule closely.
Yes, PDR requires long-term follow-up even after successful treatment. Our retina specialists use advanced imaging, including optical coherence tomography and fluorescein angiography, to monitor your retina for any signs of recurrent neovascularization or new complications. The frequency of visits depends on your treatment response and disease stability, but most patients are seen every one to three months during the first year. Consistent monitoring allows us to detect and address any changes before they threaten your vision.
What our Patients say
4.8
Reviews
(3645)